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Abstract.
Background: The association between Parkinson’s disease and lifestyle exposures such as smoking, coffee and alcohol con-
sumption have been the focus of research for several decades, with varying and often conflicting results.
Objective: This paper reviews the key features of observational studies investigating the relationship between alcohol drinking
and PD risk, to determine potential sources of variability between the results.
Methods: Relevant literature from 2000–2014 was systematically retrieved using three databases. Primary research articles were
included if they reported a measure of association between quantity and frequency of alcohol intake and PD risk, and adjusted
at least for the potential confounding factors of smoking and age.
Results: Sixteen articles were identified. The seven case-control studies were more likely to report a weak protective association
by level of alcohol consumption compared to the studies with prospective designs. Two studies reported the relationship between
heavy (harmful to health) drinking and PD. There was weak evidence that associations varied by type of alcoholic beverage.
Smoking may modify the association between alcohol intake and PD risk, however, the evidence does not support the theory that
a confounder (such as an addiction-avoiding personality trait) produced the inverse associations between smoking, coffee and
alcohol intake and PD risk. Methodological weaknesses of the studies, including selection and recall bias, residual confounding
and lack of statistical power may in part account for their differences.
Conclusion: The weak association between alcohol drinking and PD risk was found in studies at greater risk of selection and
recall bias.
Keywords: Alcohol, alcoholic beverages, alcohol drinking, Parkinson’s disease, review, risk factors, case-control studies, cohort
studies, epidemiologic methods, lifestyle
INTRODUCTION
Parkinson’s disease (PD) is the second most com-
monly occurring neurodegenerative condition after
Alzheimer’s disease [1]. Global estimates of the age-
adjusted incidence rate of PD range from 7.9 to 19 per
100,000 person-years and a prevalence of 57 to 230
per 100,000 population [2]. Various risk and protective
∗Correspondence to: Dr. Silvana Bettiol, School of Medicine,
University of Tasmania, Medical Sciences Precinct, 17 Liverpool St,
Hobart, Tasmania, 7000, Australia. Tel.: +61 3 62264826; E-mail:
s.bettiol@utas.edu.au.
factors of PD have been extensively investigated over
several decades, however the etiology remains largely
unclear [3]. There is a great interest in identifying
at-risk individuals early, to potentially slow down
or prevent neurodegeneration [4]. While genetic and
familial environmental exposures are often cited to
contribute to PD risk, lifestyle exposures such as smok-
ing, coffee/tea and alcohol consumption have been the
focus of research for several decades with varying and
often conflicting results.
Interest in determining the association between
alcohol consumption and risk of PD has to some extent
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come about from the inverse associations between
smoking, coffee consumption and risk of PD. Risk
reductions have been observed for caffeine consumers
and smokers [5, 6], however causality has yet to be
unequivocally established. Early studies that assessed
alcohol consumption and risk of PD produced equiv-
ocal results [7–9]. However more recently, several
meta-analyses have reported an inverse relationship
between alcohol intake and PD risk [10–12]. Whether
these factors are truly biologically protective is still a
matter of debate, and interestingly this inverse rela-
tionship is not consistent across studies. The objective
of this systematic review was to update earlier reviews
[10, 11] using a more rigorous approach and to explore
potential sources of variability by critically review-
ing the key methodological features of eligible studies,
such as study design, control of confounding and mea-
surement of exposure and outcome.
METHODS
Search strategy
The databases PubMed, TRIP [13] and Web of Sci-
ence Core Collection were searched systematically for
relevant literature. The two main constituents of the
research question; ‘Parkinson’s disease’ and ‘alcohol’,
were used to develop database search terms. These two
terms were entered into Roget’s Thesaurus online, to
identify as many synonyms as possible [14]. The final
search terms used were: (alcohol∗ OR wine OR beer
OR spirit OR sake OR liquor OR liqueur OR whisky
OR rum OR ethanol) AND (Parkinson∗ OR paralysis
agitansOR shaking palsy). In total, 2619 citations were
retrieved from three databases. Where available, filters
for ‘English language articles’ and ‘primary research
articles’ were applied to reduce the number of non-
relevant citations identified by the search. The numbers
of citations remaining after the filters were applied
were then screened for relevance using inclusion and
exclusion criteria. Following the database searches, the
reference lists of three relevant meta-analytic reviews
[10–12] were hand searched. One extra citation was
identified by this method (Fig. 1).
The inclusion and exclusion criteria were developed
to screen the search results systematically and ensure
that only relevant articles were included in the final
review. Primary research articles were included if they
were published in English language, in peer reviewed
journals between 2000 and May 2014. To be included,
studies also had to include a comparison or control
group consisting of individuals without PD, report
a measure of association between quantity and fre-
quency of alcohol intake and PD risk, and adjust at least
for the potential confounding factors of smoking and
age. Studies which reported an association between
alcoholism and PD risk were also selected for inclu-
sion. Research which measured alcohol exposure as
a binary variable only (drinker versus non-drinker),
or of cross-sectional design measuring alcohol intake
and PD prevalence at the same point in time, were
excluded.
RESULTS
Sixteen articles (reporting on seventeen studies)
were identified (Fig. 1), seven of which utilised a
case-control study design to investigate the asso-
ciation between alcohol consumption and PD risk.
Four articles used a nested case-control design and
the remaining five articles (reporting on six studies)
utilised a cohort study design. Studies were mainly
conducted in the USA (seven), with two from the
United Kingdom and one each from India, Italy,
Finland, Japan, Serbia, Singapore and Sweden. The
characteristics of the included studies are shown in
Tables 1 and 2.
Case ascertainment
Studies used a variety of methods for subject and
case ascertainment, however most used standardized
and validated scales. Reference to the criteria is found
in Tables 1 and 2. The majority of studies indi-
cated that PD diagnosis was accepted if based on a
neurologist diagnosis of several cardinal signs cor-
roborated with clinic notes and screening instrument
for cognitive impairment such as the Minimal Mental
State Examination (MMSE). Research teams indicated
reviewing the medical records. PD evaluation scales
included one or a combination of the following: the
Unified Parkinson’s Disease Rating Scale (UPDRS),
UK Parkinson’s Disease Society Brain Bank Clinic
Diagnostic Criteria, Queen Square Brain Bank Crite-
ria, International Parkinson and Movement Disorder
Society rating scale. Only three studies mentioned
the response to anti-parkinsonian drugs eg. L-dopa.
Other combinations included International Classifica-
tion of Diseases codes, DNA collection, questionnaires
and hospital discharge registers and death certificates.
Assessment grading using the Hoehn and Yahr scale
was not cited, however a number of studies screened
for cognitive impairment using the Minimal Mental
State Examination.
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Fig. 1. Flow Diagram showing the selection process and results during the study screening process.
Case-control studies
In the case-control studies (Table 1), alcohol intake
was summarised in a number of different ways. Stud-
ies reported quantity and frequency in drinks, units,
decilitres or grams per day/week, duration of drinking
in years and participants positive for an alcohol use
disorder (AUD). An AUD is a harmful pattern of drink-
ing with serious risks of physical and psychological
harm. A consequence of harmful drinking is alco-
hol dependence, characterised by a strong desire to
drink and difficulties controlling drinking according
to the Diagnostic and Statistical Manual of Mental
Disorders (DSM IV) [15]. Among the studies which
measured quantity and frequency, the reference period
over which consumption was measured also varied.
Studies asked participants to recall typical consump-
tion patterns across their lifetime [16] average alcohol
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intake over the previous month [17] and drinking habits
during the period when their alcohol consumption was
the highest [18].
The results were inconsistent in case-control studies
that compared different quantities of alcohol intake
in drinkers with non-drinkers: two studies showed a
moderately decreased risk of PD with greater quan-
tity consumed [17, 19], two showed no evidence of an
association [16, 17], and one showed a strong increased
risk of PD with higher consumption [20].
Results were also inconsistent for studies in terms
of duration of drinking. A study conducted in Italy
showed evidence of a decreased risk of PD with ≥46
years of wine drinking (OR 0.45; 95% CI [0.29,
0.68]) [19]. Yet in India, consuming alcohol for >20
years was not associated with PD risk (OR 1.48; 95%
CI [0.82, 2.65]), and consuming alcohol for ≤20 years
was nearly protective (OR 0.45; 95% CI [0.20, 1.01])
[21]. However, only 48 cases and 59 controls consumed
alcohol at all so this finding may be due to a lack of
power in this study [21].
Some of the studies also showed a dose-response
relationship with level of alcohol exposure (quantity
and/or frequency) and risk of PD, albeit in oppos-
ing directions [17, 19, 20]. Nicoletti et al. [19], found
reduced risks with greater quantity of wine consumed
per day, and for units consumed per week. Evans et al.
[17], calculated an OR of 0.44; 95% CI [0.26, 0.75]
for each category of intake, while Sipetic et al. [20],
reported an increased risk for average weekly con-
sumption in decilitres (OR 4.68; 95% CI [2.79, 7.84]).
Prospective studies
Most studies reported alcohol intake in grams per
day, [22–25], however drinks per day [26, 27], or month
[28], and units per week [29], were also used (Table 2).
In the prospective studies there was no convincing
evidence of a decreased likelihood of PD according to
different levels of total alcohol consumption [22–30],
Most studies observed non-significant associations
between alcohol and PD risk. A study conducted in Fin-
land found those who consumed <5 grams of alcohol
per day had an increased risk of PD compared to non-
drinkers (RR 1.94; 95% CI [1.09, 3.47]) [24]. Another
study from the USA found increased risks of PD among
men who consumed 10 to 19.9 grams/day (RR 1.48;
95% CI [1.09, 2.01]) and women who consumed 10 to
14.9 grams/day (RR 1.67; 95% CI [1.06, 2.64]) com-
pared to non-drinkers, however there was no clear trend
of increasing risk with increasing consumption [23].
The largest study found no association between total
alcohol intake and future PD risk, however beverage
specific analyses revealed heavy liquor drinking (at
least two drinks/day) to be associated with an increased
risk (RR 1.35; 95% CI [1.02, 1.80]), and low to mod-
erate beer drinking (less than one drink/day) with a
deceased risk (RR 0.79; 95% CI [0.68, 0.92]) [26].
There was some evidence to suggest that smoking
modified the association between alcohol consump-
tion and PD risk, with greater risk reductions afforded
to ‘never smokers’. Four studies performed stratified
analyses to investigate whether the risk of PD due to
alcohol consumption, differed between ‘ever smok-
ers’ and ‘never smokers’ [22, 23, 25, 26]. All four
observed non-significant associations between total
alcohol intake and risk of PD. However, three of these
studies [22, 25, 26], found that ‘never smokers’ who
consumed alcohol had a greater risk reduction of PD
than ‘ever smokers’. Wirdefeldt et al. [25], found a pro-
tective effect of alcohol (OR 0.56; 95% CI [0.39, 0.80])
for ‘ever’ versus ‘never’ drinkers when restricting the
analysis to ‘never smokers’. Herna´n et al. [22], found
a marginally reduced risk among male ‘never smok-
ers’ who drank ≥15 grams/day (RR 0.5; 95% CI [0.3,
1.0]), but not for women. Liu et al. [26], observed an
inverse association between beer drinking and PD risk
among ‘never smokers’, however no such association
was found for liquor drinking. Conversely, Palacios
et al. did not find any significant differences when con-
ducting stratified analyses between ‘never’ and ‘ever’
smokers [23]. Further investigations would be required
to confirm these findings.
DISCUSSION
Quality of studies
This review determined several possible method-
ological weaknesses that could explain the varying and
often conflicting results of studies reporting lifestyle
exposures such as smoking, coffee/tea and alcohol con-
sumption contributing to PD risk.
Among the case-control studies there was a poten-
tial for selection bias due to selection or self-selection
of controls [17, 19, 20]. One study found an increased
risk of PD due to alcohol consumption, however they
used hospital controls receiving treatment for chronic
pancreatitis, a condition strongly associated with alco-
hol consumption [20]. Bias may have been introduced
if these controls consumed alcohol at a different rate
to the general population.
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Few case-control studies used incident cases
[16, 20], and this may have increased the potential
for inaccurate recollection of exposure. The tempo-
ral sequence of events was particularly unclear for
one case-control study, where prevalent cases were
questioned about their current alcohol intake over the
past month [17]. This study found a dose-dependent
inverse association between alcohol intake and PD
risk. Whereas a prospective cohort study reported PD
cases significantly reduced their alcohol intake around
the time of their diagnosis and continued to reduce
their alcohol intake thereafter [23]. Thus findings from
case-control studies that indicate protective effects of
alcohol should be interpreted cautiously not only for
their limitations and potential for selection bias but
also retrospective assessment of alcohol intake, since
the recall of past dietary exposures can be affected by
current exposures [31].
In further support of this argument, the studies
with the most certain temporal sequence of events
i.e. those which used cohort and nested case-control
study designs [22, 23, 26, 28, 29, 30], tended to find
non-significant associations, close to unity, between
total alcohol consumption and risk of PD. One nested
case-control study found lower risks when alcohol con-
sumption was reported by prevalent cases, compared
to incident cases who were identified five years after
alcohol exposure information was collected [28].
Two nested case-control studies may have inadver-
tently included prevalent cases in their baseline sample,
which could potentially explain the non-significant
inverse associations they observed [25, 27]. One of
these studies seemingly made no attempt to exclude
the 26 prevalent cases from their analyses [27].
There was no discernible pattern in the results
according to the length of follow-up in the prospec-
tive studies which varied between 10 years to 20 years
(Table 2). For example a nested case-control study fol-
lowed participants between 1995 and 2001 [29], yet
found very similar results to studies that had much
longer follow-up periods [22, 23, 26]. Three studies
reduced the potential for reverse causality by exclud-
ing the first 5 to 10 years of follow-up [23, 24, 26].
Two of these studies observed non-significant asso-
ciations between total alcohol intake and PD [23, 26],
and one study found increasing PD risk with increasing
duration between exposure and outcome [24].
The cohort studies were more likely to use
validated questionnaires to elicit alcohol exposure
information compared to the case-control and nested
case-control studies. All cohort studies asked partici-
pants about their consumption of specific beverages.
These questions have been shown to produce higher
estimates and improved recall of alcohol consumption
compared to questions on overall consumption alone
[32]. For these reasons, the cohort studies may have
been more likely to produce valid results.
Overall, most studies used non-drinkers as the ref-
erence category in their analyses, which helped when
comparing the results, however the definition of a
‘non-drinker’ tended to differ between studies. Apart
from the study that measured ‘peak’ alcohol consump-
tion, it was not clear whether any of the studies that
measured quantity and frequency, separated lifetime
abstainers from former drinkers. This can lead to mis-
classification if former heavy drinkers are classified as
‘non-drinkers’ [33].
Alcohol use disorders
Two studies Brighina et al. and Herna´n et al. classi-
fied alcohol exposure according to clinical criteria for
drinking that is harmful to health [34, 29]. Brighina
et al. a case-control study, screened subjects for an alco-
hol use disorder with the CAGE questionnaire and also
with medical records, using an alcohol-related medi-
cal problem as a proxy for alcoholism [34]. The CAGE
questionnaire consists of four questions and is used as a
screening tool for alcohol abuse and dependence [35].
Herna´n et al. a prospective study, classified subjects as
clinically-defined alcoholics, before their index date,
based on a computerized diagnosis of alcoholism or
alcohol-related chronic disease such as alcohol cirrho-
sis or alcoholic cardiopathy [29].
Brighina et al. found a statistically significant
inverse association between subjects with a CAGE
score of 2 or more (indicative of an alcohol use dis-
order) compared with participants with CAGE score
<2 and PD risk: adjusted OR 0.63, 95% CI [0.43,
0.93] [34]. The CAGE questionnaire positively identi-
fied 7.2% of cases and 11% of controls (based on 779
case-control pairs) for alcohol use disorders reporting
a weak but statistically significant trend of decreasing
risk of PD with increasing CAGE score [34]. When
the analysis was based on participants with a medi-
cal history of an alcohol-related health problem (based
on 843 case-control pairs) the inverse association was
weaker. The report by Herna´n et al., indicated that alco-
holism was not associated with the risk of PD, however,
the smoking-adjusted OR of 1.09, 95% CI [0.67, 1.78]
was based on eighteen cases and 174 controls (1.72%)
receiving a diagnosis of alcoholism before the index
date [29]. This analysis was based on fewer subjects,
and may have lacked power to detect a significant
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difference. Thus, the methods used to measure alco-
hol use and the statistical power of the analyses may
explain the contrasting results of the studies.
Beverage types
Eight studies measured associations between PD
risk and the beverage types; beer, wine or liquor,
however no specific beverage type was consistently,
significantly associated with PD risk. Of these eight
studies, three found statistically significant inverse
associations. Nicoletti et al. observed a moderate, dose-
dependent protective effect of wine drinking, with an
OR of 0.45; 95% CI [0.28, 0.74] for ≥3 glasses per day
[19]. Herna´n et al. and Liu et al. each found a weak,
inverse association for beer drinking, however there
was little evidence of a dose-dependent trend [22, 26].
Three studies noted that alcohol intake and PD
vary according to different kinds of alcohol suggest-
ing increased risks of PD with consumption of specific
beverages. A case-control study by Fukushima et al.
assessed daily intake separately for each type of alco-
hol including beer, Japanese sake, Shochu, wine and
whisky. There were no significant associations with
PD, except moderate to strong, dose-dependent effects
of Japanese sake [18]. Additionally, Liu et al. reported
an increased PD risk with ≥2 drinks of liquor per day
(OR 1.35; 95% CI [1.02, 1.80]) [26]. The remaining
study by Sipetic et al. indicated strong associations for
brandy and beer, and very strong associations for liquor
and wine [20]. However, the findings of this latter study
should be interpreted with caution since the authors did
not statistically control for any confounding variables
when calculating beverage specific associations.
In contrast, Palacios et al. and Brighina et al. two
studies which investigated the relationships between
beer, wine and liquor drinking and risk of PD, found
non-significant results with associations close to unity
[23, 34], It would therefore appear that the studies
collectively paint an inconsistent picture of the rela-
tionship between PD and different beverage types.
Variance in typical beverage specific consumption pat-
terns among the studied populations could potentially
explain these inconsistencies. Cultural preferences
could result in fewer participants selecting certain bev-
erages, and thus lack of significance could reflect a
lack of power. However, four studies conducted in the
United States of America, observed different results
for the same beverage [22, 23, 26, 34].
In studies that evaluated three different alcoholic
beverage types, there was no evidence of simultane-
ously reduced or increased risks for all three beverages
beer, wine and liquor [22, 23, 26, 34]. This could indi-
cate that ingredients other than ethanol may be driving
the beverage specific associations observed.
Confounding by personality traits
Ten studies analysed the effects of alcohol con-
sumption alongside smoking and caffeine intake as
risk factors for PD. Two of these studies found sta-
tistically significant inverse associations for all three
factors [17, 19]. One of these studies also found a dose-
dependent trend for the presence of at least one, two or
three of smoking, coffee or wine drinking behaviours,
with the greatest risk reduction for all three [19]. The
other study suggested that personality traits (such as
risky, sensation seeking behaviours) confounded the
associations between each of the three factors and PD
risk [17]. These findings suggest that a confounding
variable common to all three factors may explain or
partially explain their hypothetical protective effects.
However, against this argument is that the remaining
eight studies either did not observe significant associa-
tions for all three factors or observed significant effects
but in different directions. The majority of studies did
not find simultaneously protective effects for smoking,
coffee drinking and alcohol consumption, suggesting
that the presence of a confounding variable common
to all three factors, such as an addiction-avoiding per-
sonality trait, is unlikely.
Ethnicity
Most of the selected studies examined PD risk in
western countries with predominantly white popula-
tions. Two studies recruited participants of East Asian
descent. One case-control study recruited participants
in Japan [18], and a prospective study recruited Singa-
porean Chinese participants [30]. Both studies found
non-significant associations between total alcohol con-
sumption and PD risk. Fukushima et al. calculated an
association close to unity (OR 0.96; 95% CI [0.50,
1.81]) for those who drank alcohol at least six days per
week compared to non-drinkers, and Tan et al. found a
non-significant decreased risk (RR 0.6, 95% CI [0.31,
1.16]) for at-least-weekly drinkers compared to non-
or less-than-weekly drinkers [18, 30]. Fukushima et al
collected data on ‘peak’ alcohol drinking rather than
average consumption, and statistically controlled for
a number of extra potential confounders compared to
Tan et al such as body mass index, medication history,
cholesterol, vitamin E, vitamin B6, iron and dietary
glycemic index, which could potentially explain the
differences in results [18, 30].
440 S.S. Bettiol et al. / Alcohol Consumption and Parkinson’s Disease Risk
Summary
This study has provided a critical summary of the
epidemiologic literature related to alcohol consump-
tion and PD risk published since 2000. In general,
studies with a prospective design tended to find non-
significant associations between total alcohol intake
and PD risk, with two studies finding an increased risk
with moderate alcohol consumption. The case-control
studies were more likely to find protective effects of
alcohol on PD risk, however it is unclear to what extent
these observations were the result of selection and
recall bias.
Among the reviewed studies there was some evi-
dence to suggest that smoking modifies the association
between alcohol intake and PD risk. There was also evi-
dence to suggest that beer may be inversely associated
with PD risk, however ethanol is unlikely to be the pro-
tective ingredient. The evidence does not support the
theory that a confounder, such as an addiction-avoiding
personality trait, has produced the inverse associations
between smoking, coffee and alcohol intake and PD
risk. Studies examining the relationship between alco-
hol use disorders and PD have produced inconsistent
results.
We note the lack of uniformity by these primary
studies in the definition of drinking, the inconsistency
of the units used to report quantity and frequency,
and the reference period over which alcohol consump-
tion was measured. We fully appreciate that to obtain
valid estimates of alcohol consumption, researchers
must utilise methods appropriate for the drinking cul-
ture [36]. However, these methodological differences
make it difficult to compare results across countries
with accuracy, and may explain some of the hetero-
geneity observed.
Standard measures such as units and drink por-
tions can differ between countries, therefore converting
these measures into grams of ethanol for analysis
would be beneficial for comparison. Additionally,
since the risk of PD may differ by beverage type,
researchers should aim to measure beverage specific
risks wherever possible. Not only will this help to
improve understanding of beverage specific risks but
recall may be improved compared to combined alco-
hol questioning. Whilst volume and duration of alcohol
consumption are important to determine cause-effect
associations, frequency of heavy drinking episodes
may be another important consideration [37], which
future research may wish to address.
The subject selection process was determined differ-
ently, and did not follow a uniform method across the
studies. Assessment grading using the more current
Hoehn and Yahr scale was not cited though MMSE
was used. This leaves the reader to speculate that
PD patients were selected on a scale where cognitive
decline did not interfere with the ability to recall events,
self-report exposure or complete questionnaires espe-
cially in case–control studies, a process that is prone to
recall bias and could lead to false-positive associations.
Alternatively, PD patients may underreport exposure
leading to false-negative associations.
The strengths of our review include the large number
of subjects investigated and the comprehensive pic-
ture provided. The decision to exclude studies which
did not control for the potential confounding effects
of smoking was important. Palacios et al. [23], found
smoking to be the biggest confounder of the rela-
tionship between alcohol and PD risk, and smoking
reduced the risk of PD in the majority of the reviewed
studies. The conclusions of this study are therefore
more likely to reflect the true relationship between
alcohol and PD.
A limitation to this review was the introduction of
bias. Non-published data and papers published in lan-
guages other than English were not included. Studies
which measured alcohol exposure as a binary variable
only were also excluded, however measuring exposure
as ‘ever’ or ‘never’ drinkers would have been inade-
quate to determine the complexity of alcohol exposure.
Despite identifying cohort studies, the review primar-
ily involved case-control studies and the results should
be interpreted cautiously due to the recall bias of case-
control studies.
Conclusion and implications and directions of
future research
This study highlights the need for more prospective
studies investigating the relationship between alco-
hol and PD of adequate sample size. Improvements
to reporting of studies by investigators particularly
with respect to sample size and power would help
others interpret the epidemiological significance of any
findings. We note the lack of uniformity in report-
ing quantity, duration and frequency of alcohol intake.
Researchers may wish to consider the comparability of
their results when reporting, and the need to be explicit
when presenting the data. Finally, as with any obser-
vational study, the possibility of residual confounding
cannot be ruled out. Although authors controlled for a
range of factors, it remains possible that other factors
confound the association between alcohol and PD risk.
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Interpretation of findings from case-control studies
should take into account selection and recall bias. The
association between ingredients in beer and PD risk,
and effect modification by smoking, may be avenues
for future research. The evidence is not strong enough
to recommend prioritising beer over other beverages
to reduce the risk of PD. From researchers’ responses,
most of the studies proved to be preliminary and
improving statistical power to detect joint effects was
encouraged.
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